What is iFAST Diagnostics?
Based in Southampton, England, iFAST Diagnostics is a biotechnology firm dedicated to addressing the critical challenge of resistant infections. The company's focus on this area of unmet medical need underscores its commitment to developing innovative solutions within the life sciences industry. This strategic direction is crucial in a market increasingly demanding advanced therapeutic approaches.
How much funding has iFAST Diagnostics raised?
iFAST Diagnostics has raised a total of $6.4M across 1 funding round:
Angel/Seed
$6.4M
Angel/Seed (2024): $6.4M with participation from KHP Ventures, Eink, and Raw Ventures
Key Investors in iFAST Diagnostics
KHP Ventures
KHP Ventures is a transatlantic health tech fund specializing in clinical innovators across Digital Health and MedTech. They focus on supporting ambitious founders and health tech ventures in the UK and facilitating their US growth, leveraging collaboration with health system partners to generate real-world data for broader adoption of transformative healthcare solutions.
Eink
Eink operates within the Advertising & Marketing industry, headquartered in Moshi, Maharashtra, India, with a team size of 20-49 employees and revenues between $1M-$5M.
Raw Ventures
Raw Ventures provides long-term support for companies merging transformative technology with robust business models, focusing on innovative tech ideas and outstanding founding teams. They offer strategic and operational guidance alongside financial backing, with a diverse portfolio spanning agrotech, biotech, medtech, and fintech, indicating a global investment strategy.
What's next for iFAST Diagnostics?
The recent major enterprise-level funding, characterized as a strategic investment, suggests iFAST Diagnostics is poised for significant scaling and development. This capital will likely be deployed to accelerate research and development, expand clinical trials, and potentially broaden its market reach. The company's focus on resistant infections places it at the forefront of tackling a growing global health concern, indicating a strong future trajectory.
See full iFAST Diagnostics company page
